News briefing: Precision Medicine Group acquires cell and gene therapy-focused services firm Project Farma; RoosterBio and Sartorius collab on gene therapy manufacturing
As more and more players pursue cell and gene therapies, companies are looking for ways to keep up on the manufacturing end.
On Thursday, Precision Medicine Group took the wraps off a deal to buy out Project Farma, a bioengineering services firm that supports the manufacturing and scale-up of cell and gene therapies. Project Farma will join Precision for Medicine, PMG’s research and development services arm.
“The acquisition adds Project Farma’s unique expertise to Precision’s suite of end-to-end cell and gene therapy capabilities to support development and commercialization,” Precision said in a statement.
Precision was formed in 2012 as a specialized services company supporting drug development and commercialization. Since 2013, it has supported over 70% of FDA-approved cell and gene therapies, according to CEO Mark Clein. The addition of Project Farma will give Precision “true end-to-end capabilities in cell and gene therapy,” Clein said.
“In today’s highly competitive and scrutinized advanced therapies marketplace, ensuring a safe, scalable, and high-quality manufacturing capability can be the difference between success and failure,” Precision for Medicine president Chad Clark said. — Nicole DeFeudis
RoosterBio and Sartorius to scale up cell and gene therapy manufacturing capabilities
RoosterBio and Sartorius are teaming up to boost cell and gene therapy manufacturing.
The companies announced the move Thursday, with the goal of advancing the scale-up of human mesenchymal stem/stromal cell manufacturing for regenerative medicine. By doing so, process development efforts will be reduced, supply chains will be bolstered and the development of the therapies themselves will be accelerated, they said.
“Taking hMSC manufacturing to the thousand-liter scale is critical in meeting product dose requirements in commercial manufacturing,” said RoosterBio CEO Margot Connor in a statement.
RoosterBio owns a series of hMSC working cell banks, and the collaboration will aim to pair these banks and its corresponding processing systems with Sartorius’ single-use manufacturing technologies. Sartorius’s scalable bioreactors will then be used to scale up to 50 liters as part of this collaboration, with the system able to scale further to up to 2000 liters. — Max Gelman